This was provided at a conference taking place here in Vegas this weekend! By a very well versed contact. https://www.a4m.com/longevity-fest-2025.html I have added the conference info for context! I for one have just placed a large order with my Research Only Contact! Great news on the Telehealth Front.

🔹 Who was in this trial? Adults who were obese or overweight and had knee osteoarthritis – so not a general population weight-loss study. 🔹 Dosing details Participants started at 2 mg once weekly and increased every 4 weeks until hitting 9 mg or 12 mg. These new results are based on those high doses (9–12 mg). More data is expected in 2026, including info on the planned 4 mg maintenance dose. 🔹 Weight loss: Retatrutide vs Tirzepatide - Retatrutide 12 mg: ~28.7% average body-weight reduction at 68 weeks - For reference - Tirzepatide (Zepbound) max dose: ~21–22% average weight loss at 72 weeks So yes, Retta is looking very powerful on the scale. 🔹 Side effects & discontinuations - Adverse-event–related discontinuations: - Dysesthesia (skin/nerve sensitivity) 🫀 Heart rate note: This particular trial summary didn’t mention heart rate changes at all — which is interesting, because when I tried a very low “micro” dose of Retta transitioning off tirzepatide, I personally noticed an increased resting heart rate, and with my anxiety that was a no-go. Everyone’s nervous system and tolerance is different — and Retatrutide is still investigational, not FDA approved. 📌 Education only, not medical advice. I’m a coach and educator, not a prescriber. Always work with a licensed provider before starting or changing any medication. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

RETA (retatrutide) talk is everywhere right now. I’ve been hearing the buzz that it could be up for FDA approval in early 2026. While the exact timing isn’t confirmed, retatrutide is still in Phase 3, with many projections pointing toward a filing around –early 2026. Either way, this drug is a big deal in the GLP-1 world. RETA is a triple agonist (GLP-1 + GIP + glucagon), which is part of why there’s so much excitement around its metabolic potential. My personal experience: I tried to switch from tirzepatide to RETA a few months ago. I started conservatively at 0.5 mg once weekly, but within about two days of the first dose I had a noticeably raised heart rate. Because I already deal with anxiety, that combo wasn’t a good mix for me. I took a break and tried again — same result. So for now, RETA just doesn’t seem to match my biology. Why this might happen: Because RETA activates the glucagon receptor, it may increase energy expenditure, and clinical data have shown dose-related increases in heart rate that researchers are still working to fully understand. Also may be longer to see full appetite suppression because of the metabolic activation. I’m sharing this to normalize something important: Even the most exciting next-gen meds aren’t one-size-fits-all. See the full chart below for some clinical data I combined :) I’d love to hear your experiences — especially if you tried it and: - loved it - couldn’t tolerate it - noticed heart rate changes or little appetite? - found a better fit staying with tirzepatide or semaglutide. (Educational discussion only — not medical advice.)